Immunogenicity of biosimilars: considerations related to evaluation strategy and challenges
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: AMARAVADI, Lakshmi (BiogenIdec, Translational Medicine, Cambridge, ma, United States of America)
As the Biosimilar landscape is rapidly evolving there is also a parallel evolution of newer technologies that allow for development improved immunogenicity assays. In addition there are a variety of scenarios that may be applicable for biosimilar immunogenicity evaluation where a biosimilar is being compared with the original therapeutic. In this.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.